Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperalgesia | 3 | 2025 | 24 | 1.550 |
Why?
|
| Plant Extracts | 7 | 2019 | 302 | 1.460 |
Why?
|
| Analgesics | 2 | 2025 | 55 | 1.190 |
Why?
|
| Ethanol | 4 | 2025 | 224 | 1.140 |
Why?
|
| Ganglia, Spinal | 2 | 2025 | 42 | 1.090 |
Why?
|
| Alcoholic Neuropathy | 1 | 2025 | 1 | 0.960 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2025 | 4 | 0.960 |
Why?
|
| KCNQ Potassium Channels | 1 | 2025 | 5 | 0.950 |
Why?
|
| Nociceptors | 1 | 2025 | 30 | 0.940 |
Why?
|
| Respiratory Rate | 1 | 2025 | 11 | 0.920 |
Why?
|
| Polysomnography | 1 | 2025 | 43 | 0.910 |
Why?
|
| Neuralgia | 1 | 2025 | 22 | 0.880 |
Why?
|
| Patch-Clamp Techniques | 1 | 2024 | 228 | 0.850 |
Why?
|
| Sleep | 1 | 2025 | 185 | 0.800 |
Why?
|
| Nocturnal Enuresis | 1 | 2023 | 1 | 0.780 |
Why?
|
| Capparis | 2 | 2012 | 2 | 0.700 |
Why?
|
| Low Back Pain | 1 | 2022 | 101 | 0.690 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2024 | 298 | 0.690 |
Why?
|
| Cyclobutanes | 1 | 2021 | 3 | 0.680 |
Why?
|
| Fruit | 3 | 2012 | 178 | 0.680 |
Why?
|
| Shaker Superfamily of Potassium Channels | 1 | 2021 | 5 | 0.680 |
Why?
|
| Phytotherapy | 2 | 2012 | 75 | 0.680 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 11 | 0.670 |
Why?
|
| Heart Diseases | 1 | 2021 | 112 | 0.610 |
Why?
|
| Action Potentials | 1 | 2021 | 246 | 0.590 |
Why?
|
| Rats | 6 | 2025 | 3735 | 0.590 |
Why?
|
| Myocytes, Cardiac | 1 | 2021 | 183 | 0.570 |
Why?
|
| Hypericum | 2 | 2007 | 4 | 0.520 |
Why?
|
| Animals | 14 | 2025 | 16992 | 0.490 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2025 | 1766 | 0.470 |
Why?
|
| Fibrinolytic Agents | 2 | 2012 | 24 | 0.430 |
Why?
|
| Biosensing Techniques | 1 | 2016 | 136 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2025 | 1124 | 0.420 |
Why?
|
| Isoxazoles | 1 | 2013 | 15 | 0.420 |
Why?
|
| Methanol | 2 | 2012 | 22 | 0.420 |
Why?
|
| Diabetic Neuropathies | 1 | 2013 | 12 | 0.410 |
Why?
|
| Anticonvulsants | 1 | 2013 | 40 | 0.410 |
Why?
|
| Thrombosis | 2 | 2012 | 81 | 0.410 |
Why?
|
| Edema | 1 | 2012 | 26 | 0.370 |
Why?
|
| Lythraceae | 1 | 2011 | 3 | 0.360 |
Why?
|
| Crataegus | 1 | 2010 | 2 | 0.340 |
Why?
|
| Research | 1 | 2011 | 181 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 187 | 0.320 |
Why?
|
| Computer Simulation | 2 | 2011 | 408 | 0.320 |
Why?
|
| Rats, Wistar | 3 | 2021 | 283 | 0.310 |
Why?
|
| Pain Measurement | 1 | 2010 | 183 | 0.300 |
Why?
|
| Male | 9 | 2025 | 23409 | 0.290 |
Why?
|
| Models, Biological | 1 | 2011 | 712 | 0.280 |
Why?
|
| Antioxidants | 1 | 2011 | 443 | 0.270 |
Why?
|
| Caffeine | 1 | 2007 | 28 | 0.260 |
Why?
|
| Tremor | 1 | 2006 | 9 | 0.250 |
Why?
|
| Apoptosis | 2 | 2011 | 1568 | 0.250 |
Why?
|
| Mice | 6 | 2023 | 6644 | 0.240 |
Why?
|
| Motor Activity | 2 | 2011 | 437 | 0.230 |
Why?
|
| Infrared Rays | 1 | 2025 | 21 | 0.230 |
Why?
|
| Child | 2 | 2024 | 3443 | 0.230 |
Why?
|
| Constriction | 1 | 2025 | 4 | 0.230 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2006 | 126 | 0.230 |
Why?
|
| Monitoring, Physiologic | 1 | 2025 | 39 | 0.230 |
Why?
|
| Acromegaly | 1 | 2025 | 3 | 0.230 |
Why?
|
| Turkey | 1 | 2024 | 23 | 0.220 |
Why?
|
| Thyroxine | 1 | 2024 | 22 | 0.220 |
Why?
|
| Thyrotropin | 1 | 2024 | 24 | 0.220 |
Why?
|
| Thyroid Hormones | 1 | 2024 | 35 | 0.220 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 1596 | 0.220 |
Why?
|
| Humans | 10 | 2025 | 43102 | 0.220 |
Why?
|
| Triglycerides | 1 | 2025 | 147 | 0.210 |
Why?
|
| Movement | 2 | 2022 | 119 | 0.210 |
Why?
|
| Potassium Channels | 1 | 2024 | 80 | 0.210 |
Why?
|
| Potassium | 1 | 2024 | 109 | 0.210 |
Why?
|
| Nitric Oxide | 1 | 2007 | 386 | 0.210 |
Why?
|
| Cell Culture Techniques | 1 | 2024 | 152 | 0.210 |
Why?
|
| Down-Regulation | 1 | 2025 | 456 | 0.200 |
Why?
|
| Urinary Bladder | 1 | 2023 | 30 | 0.190 |
Why?
|
| Physical Examination | 1 | 2023 | 45 | 0.190 |
Why?
|
| Range of Motion, Articular | 1 | 2022 | 37 | 0.190 |
Why?
|
| Insulin Resistance | 1 | 2025 | 201 | 0.190 |
Why?
|
| Posture | 1 | 2023 | 61 | 0.190 |
Why?
|
| Blood Glucose | 1 | 2025 | 389 | 0.190 |
Why?
|
| Lumbar Vertebrae | 1 | 2022 | 44 | 0.190 |
Why?
|
| Algorithms | 1 | 2025 | 509 | 0.180 |
Why?
|
| Comorbidity | 1 | 2024 | 737 | 0.180 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 719 | 0.180 |
Why?
|
| Carrageenan | 2 | 2012 | 16 | 0.180 |
Why?
|
| Retrospective Studies | 2 | 2025 | 2544 | 0.170 |
Why?
|
| Cells, Cultured | 1 | 2024 | 1621 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 114 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2021 | 388 | 0.150 |
Why?
|
| Hyperkinesis | 2 | 2011 | 7 | 0.150 |
Why?
|
| Antithrombins | 1 | 2019 | 3 | 0.150 |
Why?
|
| Hemostatics | 1 | 2019 | 10 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2011 | 341 | 0.150 |
Why?
|
| Calcium | 1 | 2021 | 491 | 0.140 |
Why?
|
| Motion | 1 | 2017 | 31 | 0.140 |
Why?
|
| Time Factors | 2 | 2021 | 1857 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 532 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3156 | 0.120 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2016 | 66 | 0.120 |
Why?
|
| Female | 4 | 2025 | 24698 | 0.110 |
Why?
|
| Ondansetron | 1 | 2013 | 3 | 0.110 |
Why?
|
| Ketanserin | 1 | 2013 | 4 | 0.110 |
Why?
|
| Carbamazepine | 1 | 2013 | 4 | 0.110 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2013 | 5 | 0.100 |
Why?
|
| Streptozocin | 1 | 2013 | 26 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2013 | 15 | 0.100 |
Why?
|
| Adolescent | 1 | 2024 | 6081 | 0.100 |
Why?
|
| Morphine | 1 | 2013 | 69 | 0.100 |
Why?
|
| Flowers | 1 | 2012 | 20 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2012 | 64 | 0.090 |
Why?
|
| Picrates | 1 | 2011 | 7 | 0.090 |
Why?
|
| Ellagic Acid | 1 | 2011 | 4 | 0.090 |
Why?
|
| Tungsten Compounds | 1 | 2011 | 16 | 0.090 |
Why?
|
| Molybdenum | 1 | 2011 | 22 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 53 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 76 | 0.090 |
Why?
|
| Agmatine | 1 | 2011 | 17 | 0.090 |
Why?
|
| Phenols | 1 | 2011 | 107 | 0.080 |
Why?
|
| Plant Leaves | 1 | 2010 | 136 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2010 | 411 | 0.080 |
Why?
|
| Curcumin | 1 | 2010 | 118 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 465 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 94 | 0.070 |
Why?
|
| Arginine | 1 | 2007 | 75 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1271 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2007 | 135 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1070 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1455 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 2676 | 0.050 |
Why?
|
| Behavior, Animal | 1 | 2006 | 373 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1285 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1723 | 0.040 |
Why?
|
| Iron | 1 | 2019 | 251 | 0.030 |
Why?
|
| Aged | 1 | 2025 | 8214 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2010 | 33 | 0.020 |
Why?
|
| Leukemia | 1 | 2010 | 54 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 227 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 12222 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2009 | 74 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 13872 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2009 | 108 | 0.020 |
Why?
|
| Internet | 1 | 2009 | 236 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 945 | 0.020 |
Why?
|